Bicyclomycin benzoate is a broad-spectrum antibiotic effective against both Gram-negative and Gram-positive bacteria; it inhibits lipoprotein biosynthesis and its assembly into peptidoglycan in the cell envelope of E. coli; it targets the Rho transcription termination factor in Escherichia coli, acting as a modest Rho inhibitor that disrupts the Rho molecular machinery, leading to untimely overproduction of proteins not normally constitutively expressed and resulting in cellular toxicity; it inhibits Rho poly(C)-stimulated ATP hydrolysis via a non-competitive, reversible mechanism with respect to ATP (Ki = 20 μM).